FIELD: biotechnology.
SUBSTANCE: recombinant poxvirus for the treatment of cancer is described. The specified recombinant poxvirus includes nucleic acid encoding MUC1 peptide having three variable domains of N-terminal repeats (hereinafter – VNTR), where (a) the order of placement of nucleic acids encoding at least two domains of VNTR MUC1 is different from their order of placement in PANVAC, and (b) VNTR domains are optimized by codons. The recombinant poxvirus is stable at sequential passivation of the recombinant poxvirus. A method for producing the specified poxvirus is also described.
EFFECT: invention expands the arsenal of means for fighting cancer.
16 cl, 12 dwg, 6 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY FOR CANCER TREATMENT USING RECOMBINANT MVA AND ANTIBODIES INTRODUCED INTRAVENOUSLY | 2018 |
|
RU2795103C2 |
| PROMOTERS FOR ENHANCING EXPRESSION IN POXVIRUSES | 2016 |
|
RU2753884C2 |
| PERSONALIZED VACCINE | 2018 |
|
RU2779987C2 |
| AFRICAN SWINE FEVER VACCINE | 2020 |
|
RU2819672C2 |
| DISPLAY OF AN INTEGRAL MEMBRANE PROTEIN ON EXTRACELLULAR ENVELOPED POXVIRUS VIRIONS | 2017 |
|
RU2759846C2 |
| ISOLATED RECOMBINANT VIRUS BASED ON INFLUENZA VIRUS FOR INDUCING SPECIFIC IMMUNITY TO INFLUENZA VIRUS AND/OR PREVENTING DISEASES CAUSED BY INFLUENZA VIRUS | 2021 |
|
RU2813150C2 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-COV-2 | 2020 |
|
RU2760301C1 |
| IMMUNOGENS FOR VACCINATION AGAINST HIV | 2013 |
|
RU2721274C2 |
| CODON-OPTIMIZED NUCLEIC ACID WHICH ENCODES SMN1 PROTEIN, AND USE THEREOF | 2020 |
|
RU2742837C1 |
